Agilent is a global leader in life science, diagnostics, and analytical laboratory technologies. Now growing in the cell analysis space, Agilent instruments, software, services, solutions, and people provide trusted answers to our customers' most challenging questions.
What started as a unique offering of solutions focused on understanding cellular functionality based on underlying metabolic programming has transformed into a market-leading set of innovative tools with the additions of ACEA Biosciences and BioTek Instruments – providing customers the tools they need to uncover unique cell biology, discover novel drug targets, improve preclinical in vitro toxicology, and pioneer the next generation of immunotherapies.
Explore a breadth of solutions in real-time, impedance-based analysis of cell function, real-time cell metabolism, cell imaging and microscopy, microplate readers, microplate washers, flow cytometers, and more.
For Research Use Only. Not for use in diagnostic procedures.
The rapid development of immuno-oncology therapies has transformed the cancer treatment landscape. Discovering safe, potent, and persistent immune cell products requires a complete understanding of cancer biology and immune cell properties such as activation, cell fate, cytotoxic killing, immunomodulation, and memory. With our real-time live cell analysis tools, gain deeper insights into immune cell function and its response to the immunosuppressive tumor microenvironment.
In addition, our understanding of cancer biology and the development of new drugs is steadily improving through the use of more complex in vitro cancer models that enhance the physiological relevance of assay data. 3D cell culture technologies, particularly those that form spheroid and organoid models, are at the forefront of these measures. Long-term live cell imaging is particularly useful in quantifying drug effects on these complex models.
This live virtual event will feature presentations by leading scientists from several notable institutions. Agilent, and the newest members of the Agilent family, BioTek and ACEA, will be showcasing their latest innovations in cell analysis, including product launches, software demos, and scientific posters. You will also be able to live chat with product experts from all three companies.
Register to learn more about these solutions for immuno-oncology and cancer biology applications:
Elucidate cell health, behavior, and function with the xCELLigence RTCA eSight’s dual live cell imaging and real-time impedance capabilities
Evaluate immune cell function with the new 5-laser, 30 color Novocyte Penteon benchtop flow cytometer
Target the source of cancer cell proliferation and survival in the tumor microenvironment with functional, live-cell metabolism using the new Seahorse XF HS Mini Analyzer
Discover cell programming to mount a sustained and robust antitumor response with real-time metabolic analysis which enables you to measure and tune the drivers of immune cell fate and function with Seahorse XF technology
Conduct detailed quantitative analysis of 3D cell culture systems—including complex immuno-oncology models—using kinetic imaging and powerful image analysis tools available with the BioSpa Live Cell Analysis System and Gen5™ software
Utilize efficient and robust microplate reader-based assays with the Cytation™ Cell Imaging Multi-Mode Reader to characterize cellular behavior using both 2D and 3D formats
Improve sample quality and assay reproducibility using MultiFlo™ FX Multi-Mode Dispenser optimized for long-term maintenance of biologically relevant 3D cancer model systems
For Research Use Only. Not for use in diagnostic procedures.
Scientific posters available for viewing and downloading in the Poster Hall!
*Special Announcement regarding Agilent Flow Cytometry systems – 11am EDT
Dr. DeRenzo is a pediatric oncologist and joined the Department of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children's Research Hospital, where his goal is to develop and translate promising cell therapies from the laboratory into clinical trials for pediatric patients with solid tumors and brain tumors. Prior to joining St. Jude, he performed his general pediatric training at Case Western Reserve University/Rainbow Babies and Children's Hospital, and pediatric hematology/oncology training at Baylor College of Medicine/Texas Children's Cancer and Hematology Centers, where he stayed on as faculty until transitioning to his new position at St. Jude. He grew up in Southern New Jersey, outside of Philadelphia, and never imagined living in Cleveland, Houston, or Memphis, but has enjoyed living in each of these great cities, and getting to know people from diverse parts of the US and all over the world.
David Ferrick began his career as a University of California professor, then entrepreneur and currently industry executive focused on life sciences tools, drug discovery and diagnostics specifically in the areas of immunology and cancer. He has commercialized many life science products into new and emerging markets based on nascent technologies and advanced several drug screening programs from target identification to preclinical testing. He has authored over 150 peer reviewed publications and 13 patents along with several book chapters. Dr. Ferrick received his Ph.D. in Microbiology and Immunology from Georgetown University in Washington D.C.
Sachin Katyal received his B.Sc. (Biochemistry) from the University of Alberta and received his Ph.D. (Oncology) at the Cross Cancer Institute and the University of Alberta. His post-doctoral training, at St. Jude Children’s Research Hospital, in the area of DNA damage and repair in neurodevelopment and neuro-oncology was done in the lab of Dr. Peter McKinnon; work that led to publications in internationally-renowned journals such as Nature, Nature Neuroscience and EMBO J. In 2013, Dr. Katyal began his independent academic research position at the University of Manitoba and CancerCare Manitoba where he is an Assistant Professor within the Department of Pharmacology and Therapeutics (D-PT) and, a Senior Scientist within the Research Institute of Oncology and Hematology (RIOH). Dr. Katyal’s research is CIHR- and TFRI-funded; he is the recipient of the CIHR Institute of Cancer Research 2014 Early Career Award in Cancer Research, a CIHR New Investigator award and a TFRI New Investigator Award. He serves on several scientific review committees for international academic journals and grant review panels. More recently, Sachin established industrial partnerships, which have facilitated the development of innovative technology and methodology to accelerate his DNA damage repair research program; instrumental for development of his novel high-throughput genotoxicity and drug screening facility to understand and identify new therapies against brain tumours and leukemia. Sachin is also actively involved in trainee development, mentorship and career progression through various University-, National- and International-wide initiatives, courses and workshops.
Brad has been at BioTek Instruments, INC. since 2009, first as a Principal Scientist in the Applications Group and most recently as a Field Scientist in the South Region. Brad’s early roles included optimizing new assay processes on BioTek’s line of automation, liquid handling, microplate detection, and imaging instrumentation, in addition to supporting new product development. Currently his role is supporting academic, biotech, and pharmaceutical researchers across five states. Prior to joining BioTek, he acquired extensive experience serving as an Automated Solutions Scientist and Applications Scientist with multiple reagent providers. During his 25 year career in the Biotech Industry he has worked with numerous automation and detection platforms, as well as a variety of cell models, to optimize 2D and 3D cell culture assays across multiple research fields. His current work has led to publications in Assay and Drug Development Technologies, The Journal of Laboratory Automation, The Journal of Biomolecular Screening, Cells, and Combinatorial Chemistry and High Throughput Screening, among others. Brad has additionally presented his work at numerous international conferences and workshops across the United States, Europe, and Asia.
Dr. Kirk McManus is an Associate Professor in the Department of Biochemistry and Medical Genetics at the University of Manitoba. He is also a Senior Scientist within the Research Institute of Oncology and Hematology (formerly the Manitoba Institute of Cell Biology) housed within CancerCare Manitoba. He received a BSc (1995) and an MSc (1999) from the University of Manitoba and moved to Edmonton, Alberta to conduct his PhD studies (1999) in Oncology under the supervision of Dr. Michael Hendzel. There he studied the regulation and dynamics of posttranslational histone modifications and their influence on chromosome segregation. His postdoctoral studies were performed with Dr. Phil Hieter at the Michael Smith Laboratories in Vancouver, BC, where he utilized cross-species approaches to identify genes that regulate chromosome stability and characterize their impact on cancer development. Dr. McManus joined the University of Manitoba in June, 2009, and research team is focused on identifying and characterizing genes that regulate chromosome stability in various cancer contexts including colorectal and ovarian, and exploiting these characteristics to identify novel therapeutic targets. His team currently couples genetics, biochemistry and cellular biology along with innovative digital imaging microscopy to identify the molecular determinants of chromosome instability and exploit this information using synthetic lethal strategies.
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events